Customised Viral Vectors for Cell Modelling, Gene Therapy, and Vaccination Research and Development
- Company Details
- Products & Services
- White Papers
- Press Releases
- Regional Offices
- Contact Company
Sirion Biotech to Attend ESGCT XXV Anniversary Congress
Sirion Biotech has announced it will be attending the ESGCT XXV Anniversary Congress, in collaboration with the German Society for Gene Therapy...
CAR-T Acknowledged by FDA Committee
Novartis has announced its CAR-T cell therapy CTL019 has been recommended by the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee...
Sirion Biotech Viral Vector Experience
Gene delivery by viral vectors has taken centre stage in the development of gene therapies and immuno-oncologies. It has revolutionised the precision that complex cell models can be...
Viral Vectors Engineered for Academic and Clinical Research
Off-the shelf virus vectors are naturally limited to answer only a basic set of questions. This can lead experimenters to compromise their...
Using Viral Vectors to Reach Higher Transduction Levels
Known as transduction, the application of virus particles to deliver gene constructs to a cell is one of the best and most efficient ways to genetically modify mammalian or human...
Vaccunation and Immune Oncology Tool Ad19a/64 Acts as a Prime Reagent in a Two-Step Prime Boost Vaccination Approach
Sirion Biotech has announced that the Ad19a/64 vectors, considered by insiders as a promising vaccination and immune oncolgy tool, can act as a powerful prime reagent in a two-step prime...